Venus Remedies Ltd has successfully completed the phase III clinical trials of the new formulation developed by its R&D wing with excellent results reported from all centres where the same were being carried out.

The company had begun its multi-centred phase III clinical trials for its new formulation, Fixed Dose Combination Drug of latest generation Cephalosporin with an Amino-glycoside, after receiving DCGI permission for the same last year and now the DCGI permission is awaited for its commercial launch very shortly, according to a company release.

This product provides a sure shot remedy for both HAP (Hospital acquired Pneumonia) and CAP (Community Acquired Pneumonia), and febrile neutropenia, a severe problem with Critical Care patients. The results of clinical trials have proved that this new formulation is 25 times more effective than the alone fourth generation Cephalosporin, one of the components of this new FDC. Further, the treatment span has been reduced to approx. 50% which means lesser hospitalization time, cost saving to the patients and more bed turnover for the hospitals/institutions. This premium solution is a boon for ICU patients where the doctors cannot afford to wait for culture reports for 24 to 48 hours.

The company has already filed a Patent Application for its revolutionary formulation to Indian Patent Office and a PCT application is in process for international Patent of the same. The company shall be launching this new formulation under strategic marketing tie-up with leading Pharma companies, with the brands and agreements already in place for launching the product in its niche segment.